Contents of Volume 148 · 2000

Allain H, Dautzenberg PHJ, Maurer K, Schuck S, Bonhomme D, Gérard D: Double blind study of tiapride versus haloperidol and placebo in agitation and aggressiveness in elderly patients with cognitive impairment 361
Allen RM, Dykstra LA: Role of morphine maintenance dose in the development of tolerance and its attenuation by an NMDA receptor antagonist 59
Amalric M → Smith AD
Ancione M → Spina E
Aravagiri M → Gitlin MJ
Avenoso A → Spina E

Bartzokis G → Gitlin MJ
Beekman M → Ungard JT
Belzung C, Le Guisquet AM, Crestani F: Flumazenil induces benzodiazepine partial agonist-like effects in BALB/c but not C57BL/6 mice 24
Belzung C → Griebel G
Bentura ML → Cuéllar B
Berridge CW, Morris MF: Amphetamine-induced activation of forebrain EEG is prevented by noradrenergic β-receptor blockade in the halothane-anesthetized rat 307
Bigelow GE → Strain EC
Bond AJ → Cleare AJ
Bond J → Kantak KM
Bonhomme D → Allain H
Booij J → Reneman L
Bottlender R → Gallinat J
Bowen SE, Fowler SC, Stanford JA, Kallman MJ: Behavioral tolerance to the force differentiation effects of diazepam and midazolam in rats 327
Brebner K, Phelan R, Roberts DCS: Effect of baclofen on cocaine self-administration in rats reinforced under fixed-ratio 1 and progressive-ratio schedules 314
Brink W van den → Reneman L
Briscoe RJ, Winger G, Lewis JW, Woods JH: Methoclocinnamox: time course of changes in alfentanil-reinforced responding in rhesus monkeys 393
Browning JA → Lohr JB
Brunner F → Talvik-Lotfi M
Bush DEA → DeSousa NJ

Caine SB, Negus SS, Mello NK: Effects of dopamine $D_{1\text{-like}}$ and $D_{2\text{-like}}$ agonists on cocaine self-administration in rhesus monkeys: rapid assessment of cocaine dose-effect functions 41
Caligiuri MP → Lohr JB
Calo' G → Polidori C
Campbell UC → Carroll ME
Carroll ME, Cosgrove KP, Campbell UC, Morgan AD, Mickelberg JL: Reductions in ethanol, phencyclidine, and food-maintained behavior by naltrexone pre-treatment in monkeys is enhanced by open economic conditions 412
Carroll ME → Lynch WJ
Carter BL, Tiffany ST, Conklin CA: Associative and non-associative fentanyl tolerance in the rat: evaluation of cross tolerance with mu-and kappa-specific opioids 384
Carter RB → Ungard JT
Cartmell J, Monn JA, Schoepp DD: Attenuation of specific PCP-evoked behaviors by the potent mGlu2/3 receptor agonist, LY379268 and comparison with the atypical antipsychotic, clozapine 423
Chambers LL → Mansbach RS
Ciccocioppo R → Polidori C
Cleare AJ, Bond AJ: Ipsapirone challenge in aggressive men shows an inverse correlation between 5-HT_{1A} receptor function and aggression 344
Clifford EM → Whale R
Collins SL → Kantak KM
Conklin CA → Carter BL
Cools AR → Ellenbroek BA
Cosgrove KP → Carroll ME
Costentin J → El Yacoubi M
Cousins MS, Seiden LS: The serotonin-1A receptor antagonist WAY-100635 modifies fluoxetine's antidepressant-like profile on the differential reinforcement of low rates 72-s schedule in rats 438
Cowen PJ → Whale R
Crestani F → Belzung C
Cuéllar B, Fernández AP, Lizasoain I, Moro MA, Lorenzo P, Bentura ML, Rodrigo J, Leza JC: Up-regulation of neuronal NO synthase immunoreactivity in opiate dependence and withdrawal 66
Czoty PW, Justice JBJr, Howell LL: Cocaine-induced changes in extracellular dopamine determined by microdialysis in awake squirrel monkeys 299

Dautzenberg PHJ → Allain H
DeSousa NJ, Bush DEA, Vaccarino FJ: Self-administration of intravenous amphetamine is predicted by individual differences in sucrose feeding in rats 52
DeVeaugh-Geiss J → Shiffman S
Dijkstra D → Ungard JT
Dykstra LA → Allen RM

Easterling KW, Plovnick RM, Holtzman SG: Acute opioid but not benzodiazepine dependence in rats responding for intracranial self-stimulation 263
El Yacoubi M, Ledent C, Parmentier M, Costentin J, Vaugeois J-M: The anxiogenic-like effect of caffeine in two experimental procedures measuring anxiety in the mouse is not shared by selective A_{2A} adenosine receptor antagonists 153
Elash CA → Shiffman S
Ellenbroek BA, Sluyter F, Cools AR: The role of genetic and early environmental factors in determining apomorphine susceptibility 124
Evoniuk G → Shiffman S

Facciolà G → Spina E
Farde L → Nyberg S
Farde L → Talvik-Lotfi M
Fernández AP → Cuéllar B
Fogelson D → Gitlin MJ
Fowler SC → Bowen SE
Fox BS → Kantak KM

Gallinat J, Bottlender R, Juckel G, Munke-Puchner A, Stotz G, Kuss H-J, Mavrogiorgou P, Hegerl U: The loudness dependency of the auditory evoked N1/P2-component as a predictor of the acute SSRI response in depression 404
Gasior M → Miller KA
Gasior M → Ungard JT
Gérard D → Allain H
Gerlach J: Atypical antipsychotics: an inspiring but confusing concept 1
Giovanoni K → Kantak KM
Gitlin MJ, Nuechterlein KH, Mintz J, Fogelson D, Bartzokis G, Ventura J, Subotnik K, Aravagiri M: Fluphenazine levels during maintenance treatment of recent-onset schizophrenia: relation to side effects, psychosocial function and depression 350
Gnys M → Shiffman S
Goldberg SR → Heishman SJ
Goldberg SR → Munzar P
Gommans J, Hijzen TH, Maes RAA, Olivier B: Discriminative stimulus properties of alprazolam 146
Gong Z-H → Wall A
Griebel G, Belzung C, Perrault G, Sanger DJ: Differences in anxiety-related behaviours and in sensitivity to diazepam in inbred and outbred strains of mice 164
Guerrini R → Polidori C
Gunning B → Reneman L
Gwaltney CJ → Shiffman S

Halldin C → Talvik-Lotfi M
Hegerl U → Gallinat J
Heishman SJ, Schuh KJ, Schuster CR, Henningfield JE, Goldberg SR: Reinforcing and subjective effects of morphine in human opioid abusers: effect of dose and alternative reinforcer 272
Henningfield JE → Heishman SJ
Hijzen TH → Gommans J
Hirvonen J → Jääskeläinen IP
Holtzman SG → Easterling KW
Howell LL → Czoty PW

Ito H → Talvik-Lotfi M
Izenwasser S → Katz JL

Jääskeläinen IP, Hirvonen J, Saher M, Pekkonen E, Sillanaukee P, Näätänen R, Tiitinen H: Dose-dependent suppression by ethanol of transient auditory 40-Hz response 132
Johnson AE → Wall A
Johnson MD → Ko MCH
Johnston JA → Shiffman S
Juckel G → Gallinat J
Justice JBJr → Czoty PW

Kallman MJ → Bowen SE
Kantak KM, Collins SL, Lipman EG, Bond J, Giovanoni K, Fox BS: Evaluation of anti-cocaine antibodies and a cocaine

vaccine in a rat self-administration model 251
Kapur S → Remington G
Katz JL, Izenwasser S, Terry P: Relationships among dopamine transporter affinities and cocaine-like discriminative-stimulus effects 90
Khayrallah M → Shiffman S
Kitano Y → Makino M
Ko MCH, Tuchmann JE, Johnson MD, Wiesenauer K, Woods JH: Local administration of mu or kappa opioid agonists attenuates capsaicin-induced thermal hyperalgesia via peripheral opioid receptors in rats 180
Koivisto E → Ruotsalainen S
Komiyama C → Makino M
Koob GF → Smith AD
Koshiya K → Morita T
Kuss H-J → Gallinat J

Le Guisquet AM → Belzung C
Ledent C → El Yacoubi M
Lewis JW → Briscoe RJ
Leza JC → Cuéllar B
Lipman EG → Kantak KM
Lizasoain I → Cuéllar B
Lohr JB, Caligiuri MP, Manley MS, Browning JA: Neuroleptic-induced striatal damage in rats: a study of antioxidant treatment using accelerometric and immunocytochemical methods 171
Lorenzo P → Cuéllar B
Lynch WJ, Carroll ME: Reinstatement of cocaine self-administration in rats: sex differences 196

MacDonald E → Ruotsalainen S
Madia AG → Spina E
Maes RAA → Gommans J
Makino M, Kitano Y, Komiyama C, Takasuna K: Human interferon-α increases immobility in the forced swimming test in rats 106
Manley MS → Lohr JB
Mansbach RS, Chambers LL, Rovetti CC: Effects of the competitive nicotinic antagonist erysodine on behavior occasioned or maintained by nicotine: comparison with mecamylamine 234
Mao L, Wang JQ: Motor stimulation following bilateral injection of the group-I metabotropic glutamate receptor agonist into the dorsal striatum of rats: evidence against dependence on ionotropic glutamate receptors 367
Massi M → Polidori C
Maurer K → Allain H
Mavrogiorgou P → Gallinat J
McCallum SE → Porter JH
McQuade R, Stanford SC: A microdialysis study of the noradrenergic response in rat frontal cortex and hypothalamus to a conditioned cue for aversive, naturalistic environmental stimuli 201
Mello NK → Caine SB
Meltzer HY: An atypical compound by any other name is still a … 16
Meyerson B → Wall A
Mickelberg JL → Carroll ME
Miczek KA → Tornatzky W
Miettinen R → Ruotsalainen S
Miller KA, Witkin JM, Ungard JT, Gasior M: Pharmacological and behavioral characterization of cocaine-kindled seizures in mice 74
Mintz J → Gitlin MJ
Mirza NR, Stolerman IP: The role of nicotinic and muscarinic acetylcholine receptors in attention 243
Monn JA → Cartmell J
Morgan AD → Carroll ME
Morita T, Sonoda R, Nakato K, Koshiya K, Wanibuchi F, Yamaguchi T: Phencyclidine-induced abnormal behaviors in rats as measured by the hole board apparatus 281
Moro MA → Cuéllar B
Morris MF → Berridge CW
Munke-Puchner A → Gallinat J
Munzar P, Goldberg SR: Dopaminergic involvement in the discriminative-stimulus effects of methamphetamine in rats 209

Näätänen R → Jääskeläinen IP
Nakato K → Morita T
Negus SS → Caine SB
Nordström A-L → Talvik-Lotfi M
Nuechterlein KH → Gitlin MJ
Nyberg S, Farde L: Non-equipotent doses partly explain differences among antipsychotics – implications of PET studies 22
Nyberg S → Talvik-Lotfi M

Olivier B → Gommans J

Parmentier M → El Yacoubi M
Paty JA → Shiffman S
Pekkonen E → Jääskeläinen IP
Perrault G → Griebel G
Perucca E → Spina E
Phelan R → Brebner K
Plovnick RM → Easterling KW
Polidori C, Calo' G, Ciccocioppo R, Guerrini R, Regoli D, Massi M: Pharmacological characterization of the nociceptin receptor mediating hyperphagia: identification of a selective antagonist 430
Porter JH, McCallum SE, Varvel SA, Vann RE: The discriminative stimulus properties of the atypical antipsychotic olanzapine in rats 224

Regoli D → Polidori C
Reid IC → Stewart CA
Remington G, Kapur S: Atypical antipsychotics: are some more atypical than others? 3
Reneman L, Booij J, Schmand B, Brink W van den, Gunning B: Memory disturbances in "Ecstasy" users are correlated with an altered brain serotonin neurotransmission 322
Roberts DCS → Brebner K
Rochford J → Spreekmeester E
Rodrigo J → Cuéllar B
Rovetti CC → Mansbach RS
Ruotsalainen S, Miettinen R, MacDonald E, Koivisto E, Sirviö J: Blockade of muscarinic, rather than nicotinic, receptors impairs attention, but does not interact with serotonin depletion 111
Saher M → Jääskeläinen IP
Sanger DJ → Griebel G
Schmand B → Reneman L
Schoepp DD → Cartmell J
Schuck S → Allain H
Schuh KJ → Heishman SJ
Schuster CR → Heishman SJ
Scordo MG → Spina E
Seiden LS → Cousins MS
Shiffman S, Johnston JA, Khayrallah M, Elash CA, Gwaltney CJ, Paty JA, Gnys M, Evoniuk G, DeVeaugh-Geiss J: The effect of bupropion on nicotine craving and withdrawal 33
Sillanaukee P → Jääskeläinen IP
Sirviö J → Ruotsalainen S
Sluyter F → Ellenbroek BA
Smith AD, Smith DL, Zigmond MJ, Amalric M, Koob GF: Differential effects of dopamine receptor subtype blockade on performance of rats in a reaction-time paradigm 355
Smith DL → Smith AD
Sonoda R → Morita T
Spina E, Avenoso A, Facciolà G, Scordo MG, Ancione M, Madia AG, Ventimiglia A, Perucca E: Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics 83
Spreekmeester E, Rochford J: Selective mu and delta, but not kappa, opiate receptor antagonists inhibit the habituation of novelty-induced hypoalgesia in the rat 99
Stanford JA → Bowen SE
Stanford SC → McQuade R
Stewart CA, Reid IC: Repeated ECS and fluoxetine administration have equivalent effects on hippocampal synaptic plasticity 217
Stolerman IP → Mirza NR
Stoller K → Strain EC
Stotz G → Gallinat J
Strain EC, Stoller K, Walsh SL, Bigelow GE: Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers 374
Subotnik K → Gitlin MJ
Sutherland II J → Zhang L

Takasuna K → Makino M
Talvik-Lotfi M, Nyberg S, Nordström A-L, Ito H, Halldin C, Brunner F, Farde L: High $5HT_{2A}$ receptor occupancy in M100907-treated schizophrenic patients 400
Tamminga CA: "New" rather than "atypical" 20
Terry P → Katz JL
Tiffany ST → Carter BL
Tiitinen H → Jääskeläinen IP
Tornatzky W, Miczek KA: Cocaine self-administration "binges": transition from behavioral and autonomic regulation toward homeostatic dysregulation in rats 289
Tuchmann JE → Ko MCH

Ungard JT, Beekman M, Gasior M, Carter RB, Dijkstra D, Witkin JM:

Modification of behavioral effects of drugs in mice by neuroactive steroids 336
Ungard JT → Miller KA

Vaccarino FJ → DeSousa NJ
Vann RE → Porter JH
Varvel SA → Porter JH
Vaugeois J-M → El Yacoubi M
Ventimiglia A → Spina E
Ventura J → Gitlin MJ

Walker EA → Zhang L
Wall A, Gong Z-H, Johnson AE, Meyerson B, Zhang X: Cross-tolerance in drug response and differential changes in central nicotinic and *N*-methyl-D-aspartate receptor binding following chronic treatment with either (+)- or (−)-nicotine 186
Walsh SL → Strain EC
Wang JQ → Mao L
Wanibuchi F → Morita T
Whale R, Clifford EM, Cowen PJ: Does mirtazapine enhance serotonergic neurotransmission in depressed patients? 325
Wiesenauer K → Ko MCH
Winger G → Briscoe RJ
Witkin JM → Miller KA
Witkin JM → Ungard JT
Woods JH → Briscoe RJ
Woods JH → Ko MCH

Yamaguchi T → Morita T
Young AM → Zhang L

Zhang L, Walker EA, Sutherland II J, Young AM: Discriminative stimulus effects of two doses of fentanyl in rats: pharmacological selectivity and effect of training dose on agonist and antagonist effects of mu opioids 136
Zhang X → Wall A
Zigmond MJ → Smith AD

Indexed in *Current Contents, Psychological Abstracts, Psyc* INFO, *Index Medicus* and in *EMBASE*

Subject index of Volume 148 · 2000

A_1 receptor 153
A_{2A} receptor knockout 153
A69024 355
ACTH 344
Active immunization 251
Adenosine 153
Aggressiveness 361
Agitation 361
Agonist-antagonist 374
Alcohol 132
Alfentanil 393
Alprazolam 146
Amphetamine 52, 307
Anger 344
Anti-cocaine antibody 251
Antidepressant 146
Antinociception 59, 99, 180
Antioxidant 171
Antipsychotic 361
Anxiety 24, 164, 201
Apormorphine 124
Arousal 307
Associative 384
Attention 111, 243
Atypical 3
Atypical antipsychotic 224
Auditory evoked potentials 404
Augmenting/reducing 404
Autonomic 289
Baclofen 314
BALB/c 24
Behavior 90, 367, 423, 438
Benzodiazepine 146, 164, 263, 327
Bicuculline 336
Binding 90
Body temperature 186
Buprenorphine 374, 393
Buprenorphine/naloxone 374
Bupropion 33, 209
C57BL/6 24
Capsaicin 180
Cerebellum 66
Chlordiazepoxide 263
Chloro-APB 209
Chloro-PB 209
Chlorpromazine 224
Cholinergic neurons 171
Chronic 327
Circadian rhythms 289
cis-Flupenthixol 209
Classical conditioning 384
Clinical studies 3
Closed economy 412
Clozapine 3, 83, 224, 423
Cocaine 41, 74, 90, 196, 209, 251, 289, 299, 314, 336
Cocaine vaccine 251
Conceptual models 3
Conditioning 201
Cortisol 344
CPP 367
Craving 33
Cross-tolerance 186, 384
D1 41
D_1 receptor 355
D2 41
D_2 receptor 355
D_3 receptor 355
Dementia 361
Depression 106, 404, 438
Depressive disorder 217
DHPG 367
5,7-DHT 111
Diazepam 164, 263
Discriminative-stimulus effect 90
Dizocilpine 336
DNQX 367
Dopamine 41, 209, 299
Dopamine transporter 90
Drug abuse 272
Drug discrimination 136, 146, 209, 224, 234
Dysregulation 289
Ecstasy 322
Elderly 361
Electroconvulsive stimulation 217
Elevated plus-maze 24, 164
Environmental factor 124
ERPs 132
Ethanol 132, 412
Eticlopride 355
Excitatory amino acid 367
Exploratory behaviour 186
Feeding 52
Fentanyl 136
Fentanyl tolerance 384
Flumazenil 24, 263
Fluoxetine 217
Fluphenazine plasma levels 350
Food 412
Food deprivation 430
Food intake 430
Force 327
Forced swimming test 106
Frontal cortex 201
GABA 314
Gamma-band response 132
GBR 12909 209, 299
Genetic factor 124
Glutamate 367
Growth hormone 344
Habituation 99
Haloperidol 224
Heart rate 289
High-affinity site 90
Hole board apparatus 281
Homeostasis 289
5-HT-1A receptor 438
5-HT_2 receptor 322
$5HT_{2A}$ 400
Human 272
Human brain 400
Hydromorphone 374
Hyperalgesia 180
Hypothalamus 66, 201
Immunocytochemistry 171
Inbred and outbred mouse strains 164
Individual difference 52
Interferon 106
Intracranial self-stimulation (ICSS) 263
Intravenous reinstatement 196
IPC-1010 251
Irritability 344
Kainate/AMPA 367
Kindling 74
Learning 217
Light/dark choice test 24
light/dark test 153, 164
Locomotion 367
Locomotor activity 74, 106, 336
Locus coeruleus 66
Long-term potentiation 217
Low-affinity site 90
LY379268 423
M100907 400

[^{11}C]M100907 400
Maintenance dose 59
MDMA 322
Mecamylamine 243
Medulla oblongata 66
Memory 322
Metabotropic glutamate receptor 423
Methamphetamine 74, 209, 281, 336
Methoclocinnamox 393
Mice 74, 336
Microdialysis 201, 299
Monkey 412
Morphine 263, 384
Morphine tolerance 66
Morphine withdrawal 66
Motor impairment 355
mu opioids 136
Muscarinic receptor 111
Nafadotride 355
Naloxone 374
Naltrexone 263, 412
Neuroactive steroids 336
Neuroendocrine 344
Neurogenic inflammation 180
Neuroleptic 171, 224
Neuroleptic side effects 350
Neuroleptic treatment 350
Neuropeptide Y 430
Nicotine 33, 186, 234
Nicotinic receptor 111, 186
Nitric oxide (NO) 66
NMDA 281, 367
NMDA receptor 59, 186
Nociceptin 430
Nomifensine 209
Non-associative 384
Noradrenaline 201
Noradrenergic 307
Norclozapine 83
Norepinephrine 307
Novel antipsychotics 3
Novelty 99
NPA 209
7-OH-DPAT 209
Olanzapine 3, 224
Olfactory nuclei 66
Open economy 412
Operant 327
Operant responding 393
Opiate receptor 99
Opioid 59, 263, 272
Opioid abuse 374
Opioid receptor 393
Orphanin FQ 430
Oxotremorine 243
pA_2 analysis 136
Passive avoidance 24
pCA 111
PCP 423
Pentylenetetrazol 336
Peripheral opioid receptor 180
PET 400
Phencyclidine 281, 412
Physostigmine 243
Picrotoxin 336
Plasma concentration 83
Plus-maze test 153
Positron emission tomography 400
Progressive ratio 263, 272, 412
Prolactin 344
Psychosis 423
Quetiapine 3
Raclopride 224
Rat 99, 106, 136, 146, 209, 224, 234, 243, 327
Reaction time 355
β-receptor 307
Reinforcement 52, 289
Response control 111
Response prediction 404
Reward 314
Rhesus monkey 41
Risperidone 3, 224
Ritanserin 224
SCH-23390 209
SCH58261 153
Schizophrenia 83, 281, 350, 400
Scopolamine 224, 243
Second-order schedule of drug delivery 251
Seizures 74
Selective attention 132
Self-administration 41, 52, 196, 234, 251, 272, 289, 314, 393, 412
Serotonergic lesion 111
Serotonin 344, 404
Serotonin receptor 400
Serotonin re-uptake inhibitor 438
Sertindole 3
Sex difference of drug abuse 196
Shuttle-box 201
Smoking cessation 33
SPECT 322
Spiperone 209
Squirrel monkey 299
Stereoisomer 186
Stimulant 307
Striatum 367
Sucrose 52
Susceptibility 124
Tail-withdrawal 59
Therapeutic drug monitoring 83
Thermoregulation 289
Thioridazine 224
Tiapride 361
Time course 393
Tolerance 59, 327
Training dose 136
Transient evoked 40-Hz response 132
U50,488H 384
Watermaze 217
Withdrawal 33
Yohimbine 336
ZM241385 153